Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $44.87 billion. The enterprise value is $37.55 billion.
| Market Cap | 44.87B |
| Enterprise Value | 37.55B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, before market open.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 383.24 million shares outstanding. The number of shares has decreased by -5.68% in one year.
| Shares Outstanding | 383.24M |
| Shares Change (YoY) | -5.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 9.57% |
| Owned by Institutions (%) | 73.42% |
| Float | 345.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 32.47 |
| PS Ratio | 8.71 |
| Forward PS | 10.12 |
| PB Ratio | 3.50 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.03, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.03 |
| Quick Ratio | 3.64 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.80% and return on invested capital (ROIC) is -36.63%.
| Return on Equity (ROE) | -41.80% |
| Return on Assets (ROA) | -31.20% |
| Return on Capital (ROIC) | -36.63% |
| Revenue Per Employee | $920,179 |
| Profits Per Employee | -$1.07M |
| Employee Count | 5,600 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 7.78 |
Taxes
In the past 12 months, Moderna has paid $1.17 billion in taxes.
| Income Tax | 1.17B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.83% in the last 52 weeks. The beta is 1.54, so Moderna's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | -3.83% |
| 50-Day Moving Average | 132.79 |
| 200-Day Moving Average | 103.91 |
| Relative Strength Index (RSI) | 32.65 |
| Average Volume (20 Days) | 3,819,656 |
Short Selling Information
The latest short interest is 21.60 million, so 5.64% of the outstanding shares have been sold short.
| Short Interest | 21.60M |
| Short Previous Month | 20.18M |
| Short % of Shares Out | 5.64% |
| Short % of Float | 6.25% |
| Short Ratio (days to cover) | 4.74 |
Income Statement
In the last 12 months, Moderna had revenue of $5.15 billion and -$5.97 billion in losses. Loss per share was -$15.66.
| Revenue | 5.15B |
| Gross Profit | 1.16B |
| Operating Income | -5.14B |
| Pretax Income | -4.80B |
| Net Income | -5.97B |
| EBITDA | -4.22B |
| EBIT | -4.80B |
| Loss Per Share | -$15.66 |
Balance Sheet
The company has $8.52 billion in cash and $1.21 billion in debt, giving a net cash position of $7.31 billion or $19.08 per share.
| Cash & Cash Equivalents | 8.52B |
| Total Debt | 1.21B |
| Net Cash | 7.31B |
| Net Cash Per Share | $19.08 |
| Equity (Book Value) | 12.82B |
| Book Value Per Share | 33.44 |
| Working Capital | 7.22B |
Cash Flow
In the last 12 months, operating cash flow was -$2.88 billion and capital expenditures -$790.00 million, giving a free cash flow of -$3.67 billion.
| Operating Cash Flow | -2.88B |
| Capital Expenditures | -790.00M |
| Free Cash Flow | -3.67B |
| FCF Per Share | -$9.61 |
Margins
Gross margin is 22.43%, with operating and profit margins of -99.73% and -115.82%.
| Gross Margin | 22.43% |
| Operating Margin | -99.73% |
| Pretax Margin | -93.19% |
| Profit Margin | -115.82% |
| EBITDA Margin | -81.95% |
| EBIT Margin | -93.19% |
| FCF Margin | -71.26% |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.68% |
| Shareholder Yield | 5.68% |
| Earnings Yield | -13.30% |
| FCF Yield | -8.18% |
Analyst Forecast
The average price target for Moderna is $139.80, which is 19.42% higher than the current price. The consensus rating is "Hold".
| Price Target | $139.80 |
| Price Target Difference | 19.42% |
| Analyst Consensus | Hold |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 14.63% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 7.8 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.8 |
| Piotroski F-Score | 3 |